Stephen Pianko

Pinnacle Clinical Research

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Stuart C. Gordon

Henry Ford Health System

Stanislas Pol

Institut Cochin

Robert Reindollar

Gilead Sciences (United States)

Marı́a Buti

Vall d'Hebron Hospital Universitari

Marc Bourlière

Hôpital Saint Joseph

Franco Felizarta

Bakersfield College

Joel E. Gallant

Gilead Sciences (United States)

Victor de Lédinghen

Hôpital Cardiologique du Haut-Lévêque

Jens Kort

AbbVie (United States)

Edward Tam

Canadian Society of Intestinal Research

Cooperative Institutions

Inserm

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Gilead Sciences (United States)

Monash University

Harvard University

Medical University of Vienna

Monash Health

Creative Research Enterprises (United States)

Instituto de Salud Carlos III

University of Chicago

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Identify, screen and treat via electronic pathway (I-STEP): an innovative approach to wait list management for general liver hospital outpatient referrals

Journal of Hepatology (2023)

Eliza Flanagan Stephen Pianko Julianne Grant Edward Saxby Sally Bell

10.1016/s0168-8278(23)02357-7

Cite

Citations (0)

The use of topical calcineurin inhibitors for pyoderma gangrenosum in inflammatory bowel disease: A case series

Gastroenterology Hepatology and Endoscopy (2020)

Poornima Varma Ashley Bloom Kurvi Patwala Kristin B. Taylor Peter De Cruz

Pyoderma

10.15761/ghe.1000193

Cite

Citations (0)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Hepatology (2017)

Fred Poordad Stanislas Pol Armen Asatryan Marı́a Buti David Shaw

Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN‐1 Part 2 was a randomized, open‐label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)‐free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and past VF on at least one NS3/4A protease and/or NS5A inhibitor‐containing therapy. Patients with compensated liver disease, with or without cirrhosis, and HCV genotype (GT) 1, 4, 5, or 6 were randomized 1:1 to receive 12 or 16 weeks of G/P. The primary endpoint was sustained virological response (SVR) at 12 weeks posttreatment (SVR12). Among 91 patients treated, 87 had GT1 and 4 had GT4 infection. SVR12 was achieved by 89% (39 of 44) and 91% (43 of 47) of patients who received 12 and 16 weeks of G/P, respectively. Virological relapse occurred in 9% (4 of 44) of patients treated with 12 weeks of G/P; there were no relapses with 16 weeks of treatment. Past treatment history with one class of inhibitor (protease or NS5A) had no impact on SVR12, whereas past treatment with both classes of inhibitors was associated with lower SVR12 rate. The most common adverse event (AE) was headache (≥10% of patients), and there were no serious AEs assessed as related to study drugs or AEs leading to discontinuation. Conclusion: Sixteen weeks of G/P treatment achieved a high SVR12 rate in patients with HCV GT1 infection and past failure to regimens containing either NS5A inhibitors or NS3 protease inhibitors. (Hepatology 2018;67:1253‐1260)

Discontinuation

Clinical endpoint

NS5A

Hepatitis C

Protease inhibitor (pharmacology)

10.1002/hep.29671

Cite

Citations (133)

ELEVATED SERUM IL-8 AND TNF ARE ASSOCIATED WITH ACUTE-PANCREATITIS

Gastroenterology (1993)

Stephen Pianko Rinaldo Bellomo Peta Tipping Ian Farragher Korman Mg

Source

Cite

Citations (2)

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

The Lancet (2019)

Zobair M. Younossi Vlad Ratziu Rohit Loomba Mary E. Rinella Quentin M. Anstee

Obeticholic acid

Steatohepatitis

Interim analysis

Clinical endpoint

Chronic liver disease

10.1016/s0140-6736(19)33041-7

Cite

Citations (1,021)

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure

Journal of Virus Eradication (2017)

Fred Poordad Stanislas Pol Armen Asatryan Marı́a Buti David Shaw

10.1016/s2055-6640(20)30790-1

Cite

Citations (0)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

New England Journal of Medicine (2017)

Marc Bourlière Stuart C. Gordon Steven L. Flamm Curtis Cooper Alnoor Ramji

Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options.We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks. Patients who were infected with HCV of other genotypes (114 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group. In POLARIS-4, patients with HCV genotype 1, 2, or 3 infection who had previously received a DAA regimen but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (151 patients) for 12 weeks. An additional 19 patients with HCV genotype 4 infection were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.In the three active-treatment groups, 46% of the patients had compensated cirrhosis. In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0% with placebo. In POLARIS-4, the rate of response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir. The most common adverse events were headache, fatigue, diarrhea, and nausea. In the active-treatment groups in both trials, the percentage of patients who discontinued treatment owing to adverse events was 1% or lower.Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed. (Funded by Gilead Sciences; POLARIS-1 and POLARIS-4 ClinicalTrials.gov numbers, NCT02607735 and NCT02639247 .).

Sofosbuvir

10.1056/nejmoa1613512

Cite

Citations (527)

LivR Well: a feasibility study for a home-based, multidisciplinary liver optimization program for the first 28 days after an admission for acute-on-chronic liver failure

Journal of Hepatology (2022)

Natalie Ngu Edward Saxby Patricia M. Anderson Lisa Stothers Anita Figredo

10.1016/s0168-8278(22)01048-0

Cite

Citations (0)